Related Experiment Video

Updated: Jul 14, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Epidermal growth factor receptor inhibitors in non-small cell lung cancer

Janet E Dancey1

  • 1Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland 20852, USA. danceyj@ctep.nci.nih.gov

Drugs
|May 25, 2007
PubMed

Insights

Aberrant epidermal growth factor receptor (EGFR) signaling drives cancer. EGFR inhibitors like gefitinib and erlotinib show modest tumor response rates in non-small cell lung cancer, with erlotinib improving survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Aberrant epidermal growth factor receptor (EGFR) signaling is a key driver of neoplastic transformation.
  • EGFR inhibition using antibodies and small molecules can impede cancer cell proliferation and survival.

Purpose of the Study:

  • To evaluate the efficacy of gefitinib and erlotinib in previously treated non-small cell lung cancer (NSCLC) patients.
  • To explore the role of specific genotypic abnormalities in predicting patient response to EGFR inhibitors.

Main Methods:

  • Retrospective analysis of patients with non-small cell lung cancer treated with gefitinib or erlotinib.
  • Assessment of objective tumor response rates and overall survival.
  • Correlation of treatment outcomes with EGFR and downstream pathway genetic mutations.

Main Results:

  • Gefitinib and erlotinib demonstrated objective tumor response rates of 8-19% in previously treated NSCLC patients.
  • Erlotinib was definitively shown to improve patient survival, unlike gefitinib.
  • The presence of specific genotypic abnormalities in EGFR or its downstream components may predict treatment benefit.

Conclusions:

  • EGFR inhibitors offer a therapeutic option for previously treated NSCLC, with erlotinib showing a survival benefit.
  • Patient selection based on molecular profiling of EGFR signaling is crucial for optimizing treatment outcomes.
  • Further research is needed to determine optimal dosing, scheduling, and combination strategies with other targeted agents.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: